HP-08-008 Efficacy of Dapoxetine in the Treatment of Premature Ejaculation Patients who Previously Failed Sertraline Therapy

Before the China SFDA approved dapoxetine for the treatment of PE, sertraline, a selective serotonin reuptake inhibitor (SSRI), was commonly used off-label to treat PE. The aim of this study was to investigate the effectiveness of dapoxetine therapy in PE patients in whom sertraline therapy failed. This study included PE patients who failed previous treatment with sertraline, and who went on to receive dapoxetine therapy in our hospital from February 2014 to February 2015. Patients who received sertraline therapy in the immediate 2 months prior to the study were excluded. All patients received dapoxetine 30 mg prn (1–3 hours before sexual intercourse) for 4 weeks. Data on their IELT and Premature Ejaculation Pro_le (PEP) were recorded before and after the completion of dapoxetine treatment regimen. Data on the Clinical Global Impression of Change (CGIC) and treatment-emergent adverse events (TEAEs) were collected in the one-month follow-up after treatment completion.